

May 29, 2006

Supratek to present results of its lead compound's phase II trial at the American Society Clinical Oncology meeting in Atlanta.

Supratek Pharma Inc., today announced that it will present an abstract outlining results of a phase II trial for its lead compound SP1049C in adenocarcinoma of the esophagus at the American Society Clinical Oncology meeting, that will be held from June 2-6, 2006, in Atlanta. The presentation will take place on Saturday, June 3rd from 8:00 AM to 12:00 PM in Bldg B, Level 1, Hall B5 and will be titled "SP1049C as first-line therapy in advanced (inoperable or metastatic) adenocarcinoma of the esophagus: A phase II window study." (Poster Number: C11, Abstract No: 4080)

SP1049C is a novel anthracycline cytotoxic designed to overcome cancer drug resistance and recently granted Orphan Drug status by the FDA for its first indication: carcinoma of the esophagus. Supratek management believes that upon successful clinical development SP1049C could become an important new cytotoxic product for improved treatment of cancer patients in a broad range of indications within the next 3-5 years.

About Supratek Pharma

Supratek Pharma is a pharmaceutical company focused on fighting metastatic cancers with innovative therapeutics. Our scientists are recognized leaders in the fields of polymer-based therapeutics and are at the forefront of the next generation pharmaceutical technology known as nanomedicine. In addition, Supratek Pharma's anti-metastasis research program led to the ground-breaking discovery of a new pathogenic pathway responsible for metastases formation and cancer progression.

Additional information on Supratek Pharma is available at <http://www.supratek.com/>.